Newsletter Life Sciences
In April, Anvisa approved the first vaccine against Chikungunya in Brazil, expanding the tools available to combat the disease. It also began requiring prescription for GLP-1-based weight loss injections in response to the indiscriminate use of these drugs. The agency updated guidelines for the registration of biological products and published guides on drug stability, in addition to opening a public consultation to review health standards in airports and aircraft.
There have been digital advances with the mandatory use of the Solicita/Datavisa system for petitions for cosmetics exempt from registration and the expansion of electronic control of special prescriptions. In the field of food safety, supplements containing ora-pro-nobis were banned due to a lack of scientific evidence of safety in high concentrations.
In the debate on professional duties, the CFM and the Federal Courts reaffirmed that only doctors can prescribe medicines, including hormonal contraceptives, blocking resolutions that sought to extend this function to pharmacists.
These actions reinforce the commitment to public health, the safe use of medicines, and the modernization of health surveillance in Brazil.